ARA-290
Also known as: Cibinetide
ARA-290 (Cibinetide) is a synthetic 11-amino-acid peptide derived from the helix-B surface of erythropoietin (EPO), developed by Araim Pharmaceuticals. It selectively activates the innate repair receptor (IRR) for anti-inflammatory, tissue-protective, and neuroprotective signaling without stimulating erythropoiesis. ARA-290 is not FDA-approved; it has received FDA Fast Track and Orphan Drug designations for sarcoidosis-associated small fiber neuropathy and remains in clinical development as of April 2026.
Who's worth your money for ARA-290
Every current seller, ranked by independent evidence — Merit Score, latest COA purity, and live $/mg (size-normalized). Prices refresh daily. Rankings are never paid.
Top Merit pick
Highest Merit Score (99) of 20 scored sellers
$54.99 · 10mg · 100.0% purity
Best value after code
$2.39/mg effective with 10% code
$42.50 · 16mg · 99.5% purity
Most tested
6 independent COAs on file
$39.00 · 12mg · 98.4% purity
Average price
$5.26/mg
Sellers
47
45-day trend
-9.1%
39 of 47 sellers have a current price· 12 stale hidden· 7 unverified hidden
Top Merit pick
🇺🇸 Glacier Aminos99✓ verified at source · just now
$5.50/mg +4.6% vs avg$54.99
10mg
- 🇺🇸 BioLongevity Labs96
✓ verified at source · just now
$6.33/mg +20.5% vs avg$95.00
15mg
- 🇺🇸 Peptide Crafters94
✓ verified at source · just now
$2.66/mg -49.5% vs avg$42.50
16mg
- 🇺🇸 Soma Peptides89
✓ verified at source · just now
$4.75/mg -9.7% vs avg$76.00
16mg
no purity - 🇺🇸 Peptidology89
✓ verified at source · just now
$5.00/mg -4.9% vs avg$54.99
11mg
- 🇺🇸 Peptide Plugs89
✓ verified at source · just now
$5.00/mg -4.9% vs avg$50.00
10mg
- 🇺🇸 Ruo Bio88
✓ verified at source · just now
$4.00/mg -23.9% vs avg$40.00
10mg
- 🇺🇸 Verified Peptides87
✓ verified at source · just now
$3.25/mg -38.2% vs avg$39.00
12mg
- 🇺🇸 EZ Peptides85
✓ verified at source · just now
$4.80/mg -8.7% vs avg$48.00
10mg
- 🇺🇸 Simple Peptide85
✓ verified at source · just now
$7.60/mg +44.6% vs avg$76.00
10mg
no purity
Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.
Watch ARA-290
Get one email when the market actually moves — no newsletter, no noise.
About ARA-290
CAS
1208243-50-8
Molecular formula
C51H84N16O21
Sequence
UEQLERALNSS
Typical dose range
4 mg/day subcutaneous (clinical trial dosing for diabetic neuropathy and sarcoidosis-associated small fiber neuropathy)
Half-life
~20 minutes terminal half-life (after 4 mg SC injection; biological effect may persist 24–72 hours)
COAs for ARA-290
56 third-party tests across 20 vendors. Each card links to the full report.
For
ARA-290
by Longeva· batch B-2026-ARA-290-10-002
For
ARA-290
by OROS Research· batch OR-LPARA32-726-B2
For
ARA-290
by Ion Peptide· batch RA10-06172026
For
ARA-290
by Ion Peptide· batch RA10-06172026
For
ARA-290
by Ion Peptide· batch RA16-06242026
For
ARA-290
by Ion Peptide· batch RA16-06242026
For
ARA-290
by Real Peptides· batch BATCH-0322
For
ARA-290
by EZ Peptides· batch EZP-ARA1005192026-03
For
ARA-290
by OROS Research· batch OR-LPARA32-526-B1
For
ARA-290
by EZ Peptides· batch EZP-ARA1005192026-03
For
Ara-290
by Ion Peptide· batch ARA16-05202026
For
Ara-290
by Ion Peptide· batch ARA16-05202026
For
ARA-290
by Riptide Wellness· batch RWARA-10-1002
For
ARA-290
by Verified Peptides· batch ARA04260312C
For
ARA-290
by Verified Peptides· batch ARA0426031 2C
For
ARA-290
by Glacier Aminos· batch ARA10GA-01
For
ARA-290
by Peptide Crafters· batch PC-G1-AR16
For
ARA-290
by Peptide Supply Co.· batch AR1022026
For
ARA-290
by Modern Research Peptides· batch LCHK262
For
ARA-290
by BioLongevity Labs· batch 2-3-46035
For
ARA-290
by Ion Peptide· batch ARA10-01212026
For
ARA-290
by Ion Peptide· batch ARA10-01212026
For
ARA-290
by BioLongevity Labs· batch cmojb6w60016nkirxxcy5khmm
For
ARA-290
by Southern Aminos· batch AR100126A
16 citations indexed for ARA-290
animal · 2026
Immunometabolic dysregulation drives selective executive cognitive dysfunction in male db/db mice
Type 2 diabetes (T2D) is associated with cognitive impairment, with executive functions such as cognitive flexibility being particularly vulnerable.
review · 2026
Peptides in Regenerative Medicine: A Comprehensive Review of Clinical Applications in Tissue Repair and Chronic Pain Management
Purpose of review This narrative review summarizes the current evidence on regenerative peptides relevant to chronic pain management, including collagen peptides, body protection compound-157 (BPC-157), thymosin beta-4 (TB-4), thymosin beta-500 (TB-500), glycyl-L-histidyl-L-lysine copper (GHK-Cu), growth hormone-relate…
review · 2025
Beyond perfusion: a review of peptide radiopharmaceuticals for cardiovascular imaging
Cardiology is continually evolving towards increased personalization with targeted diagnostics and therapeutics.
animal · 2022
Early monocyte modulation by the non-erythropoietic peptide ARA 290 decelerates AD-like pathology progression
Alzheimer's disease (AD) pathology is characterized by amyloid-β (Aβ) deposition and tau hyper-phosphorylation, accompanied by a progressive cognitive decline. Monocytes have been recently shown to play a major role in modulating Aβ pathology, and thereby have been pointed as potential therapeutic targets.
animal · 2021
Synthesis and evaluation of <sup>99m</sup>Tc-DOTA-ARA-290 as potential SPECT tracer for targeting cardiac ischemic region
Objectives Myocardial infarction caused by ischemia of heart tissue is the main reason for death worldwide; therefore, early detection can reduce mortality and treatment costs.
animal · 2016
A Nonhematopoietic Erythropoietin Analogue, ARA 290, Inhibits Macrophage Activation and Prevents Damage to Transplanted Islets
Background Erythropoietin exerts anti-inflammatory, antiapoptotic, and cytoprotective effects in addition to its hematopoietic action. A nonhematopoietic erythropoietin analogue, ARA 290, has similar properties.